ERR1 and PGC1α associated mitochondrial alterations correlate with pan-cancer disparity in African Americans.
暂无分享,去创建一个
G. Michailidis | Patricia D. Castro | M. Ittmann | A. Sreekumar | D. Piyarathna | N. Putluri | James M. Arnold | B. Karanam | A. Sikora | N. Navone | V. Sandulache | Wendong Yu | S. Lloyd | Akhila Balasubramanian | Jeffrey A. Jones
[1] M. Stern,et al. Mitochondrial biology and prostate cancer ethnic disparity , 2018, Carcinogenesis.
[2] M. Salifu,et al. Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. , 2017, Colorectal cancer.
[3] F. Deng,et al. Molecular mechanisms involving prostate cancer racial disparity. , 2017, American journal of clinical and experimental urology.
[4] Jeff S. Jasper,et al. ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. , 2016, Cell reports.
[5] E. Bowman,et al. Differential Serum Cytokine Levels and Risk of Lung Cancer Between African and European Americans , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[6] G. Andriole,et al. Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study , 2015, Cancer Prevention Research.
[7] O. Olopade,et al. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change , 2015, CA: a cancer journal for clinicians.
[8] T. Bethea,et al. Health Disparities and Cancer: Racial Disparities in Cancer Mortality in the United States, 2000–2010 , 2015, Front. Public Health.
[9] A. Singh,et al. Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation , 2015, Oncotarget.
[10] Bei-fang Ning,et al. Abstract 134: HNF4α inhibits liver cancer metastasis via suppression of NF-кB activity , 2014 .
[11] L. Williams,et al. Differing effects of metformin on glycemic control by race-ethnicity. , 2014, The Journal of clinical endocrinology and metabolism.
[12] Sarah J. Kurley,et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.
[13] Z. A. Abd Elmageed,et al. High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer. , 2013, Carcinogenesis.
[14] S. Ambs,et al. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. , 2011, Carcinogenesis.
[15] A. Jemal,et al. Global Cancer Statistics , 2011 .
[16] A. Jemal,et al. Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[17] A. Jemal,et al. The global burden of cancer: priorities for prevention , 2009, Carcinogenesis.
[18] I. Osman,et al. Molecular mechanisms involving prostate cancer racial disparity. , 2009, American journal of translational research.
[19] I. Powell. Epidemiology and pathophysiology of prostate cancer in African-American men. , 2007, The Journal of urology.
[20] Farin Kamangar,et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Bartek,et al. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. , 2004, DNA repair.
[23] Charles L. Hoppel,et al. Production of Reactive Oxygen Species by Mitochondria , 2003, Journal of Biological Chemistry.
[24] F. Mostofi,et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.
[25] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .